Chemed Corporation reported second-quarter 2026 adjusted earnings per share of $6.06, up 41.9% year over year and surpassing the Zacks Consensus Estimate by 9.2%. Revenues totaled $673.3 million, up 8.8% from the year-ago quarter and topping estimates by 1.9%. The company raised its 2026 guidance, now expecting adjusted EPS in the range of $25.00-$25.75, up from the previous $24.00-$24.75, and revenue growth excluding Medicare Cap of 8.25-9.25%, up from 6.5-7.5%. Shares have gained about 1.7% since the earnings report, underperforming the S&P 500, and analysts have made no estimate revisions in the past two months. Chemed holds a Zacks Rank #3 (Hold) with a VGM Score of B.
Chemed CorpChemed beats Q2 estimates and raises 2026 guidance, boosting earnings outlook.
Quest Diagnostics Incorporated